Glypican-3
| GO Term |
|---|
| lysosome |
| plasma membrane |
| collagen-containing extracellular matrix |
| Golgi lumen |
| side of membrane |
| GO Term |
|---|
| peptidyl-dipeptidase inhibitor activity |
| Position | Description | PubMed ID | GlyTouCan ID | Source |
|---|---|---|---|---|
| 123 | N-linked (GlcNAc...) asparagine |
|
||
| 240 | N-linked (GlcNAc...) asparagine |
|
||
| 417 | N-linked (GlcNAc...) asparagine |
|
||
| 494 | O-linked (Xyl...) (glycosaminoglycan) serine |
|
||
| 508 | O-linked (Xyl...) (glycosaminoglycan) serine |
|
| Pathway Name | Organism |
|---|---|
| A tetrasaccharide linker sequence is required for GAG synthesis | Mus musculus |
| HS-GAG biosynthesis | Mus musculus |
| HS-GAG degradation | Mus musculus |
| Post-translational protein phosphorylation | Mus musculus |
| Regulation of IGF Activity by IGFBP | Mus musculus |
| Retinoid metabolism and transport | Mus musculus |
| DO ID | Disease Name | Source |
|---|---|---|
| DOID:0060248 | Simpson-Golabi-Behmel syndrome type 1 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025